Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Nov;26(11):1493-1494.
doi: 10.1016/j.cmi.2020.05.030. Epub 2020 Jun 5.

Tuberculosis sepsis after tocilizumab treatment

A C Reisinger  1 , J Hermann  2 , F R Vagena  3 , G Hackl  4 , P Eller  4
Affiliations
Case Reports

Tuberculosis sepsis after tocilizumab treatment

A C Reisinger et al. Clin Microbiol Infect. 2020 Nov.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) Computed tomography scan of the abdomen showing a retroperitoneal lymph node bulk with necrotic transformation, and splenomegaly with multiple abscesses. (B) Abdominal sonography showing multiple splenic abscesses. (C) Hematoxylin and eosin (HE) staining of the explanted inguinal lymph node revealing granulomas surrounded by epitheloid cells. (D) Ziehl-Neelsen staining of the lymph node with numerous acid-fast rods.
See this image and copyright information in PMC

References

    1. Wu R., Wang L., Kuo H.D., Shannar A., Peter R., Chou P.J., et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. 2020;6:56–70. doi: 10.1007/s40495-020-00216-7. - DOI - PMC - PubMed
    1. Xu X., Han M., Li T., Sun W., Wang D., Fu B., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–10975. doi: 10.1073/pnas.2005615117. - DOI - PMC - PubMed
    1. Winthrop K.L., Mariette X., Silva J.T., Benamu E., Calabrese L.H., Dumusc A., et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors) Clin Microbiol Infect. 2018;24:S21–S40. - PubMed
    1. Yamasue M., Komiya K., Usagawa Y., Umeki K., Nureki S.I., Ando M., et al. Factors associated with false negative interferon-gamma release assay results in patients with tuberculosis: a systematic review with meta-analysis. Sci Rep. 2020;10:1607. - PMC - PubMed
    1. Ai J.W., Zhang S., Ruan Q.L., Yu Y.Q., Zhang B.Y., Liu Q.H., et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42:2229–2237. - PubMed

Publication types

MeSH terms